TRE-515 Market Summary

Key Factors Driving TRE-515 Growth

1. Progress in Phase I development and encouraging safety findings

In October 2025, Trethera announced completion of the dose-escalation portion of its Phase I solid-tumor trial. Patients received daily doses ranging from 40 mg to 1,440 mg, a 36-fold increase, with no dose-limiting toxicities reported at any tested dose. The company's independent Safety Review Committee supported completion of the dose-escalation stage, and biomarker findings indicated target engagement. These findings support continued clinical evaluation, although a favorable early safety profile does not establish efficacy or exclude uncommon or long-term adverse effects.

2. FDA Fast Track designation in prostate cancer and lung cancer

TRE-515 has received FDA Fast Track designation for metastatic castration-resistant prostate cancer and, on October 1, 2026, for use in combination with KRAS G12C inhibitors in previously treated, KRAS G12C mutation-positive non-small cell lung cancer (NSCLC). Fast Track status can facilitate communication with the FDA and potentially expedite development and review. These designations provide regulatory support for the drug's development strategy, but they do not guarantee approval or demonstrate clinical benefit.

3. Potential to improve outcomes when combined with KRAS inhibitors

KRAS G12C inhibitors have expanded treatment options for patients with mutation-positive NSCLC, but resistance and incomplete responses remain important challenges. Trethera's scientific rationale is that cancer cells may increase their dependence on the nucleoside salvage pathway under treatment stress. By inhibiting dCK, TRE-515 could potentially interfere with this metabolic escape mechanism and enhance the activity of KRAS-targeted drugs. The FDA's October 2026 Fast Track designation supports further development of this combination strategy, although its clinical benefit still needs to be demonstrated in patients.

4. Potential in metastatic castration-resistant prostate cancer

Metastatic castration-resistant prostate cancer (mCRPC) is a serious disease in which cancer progresses despite androgen-deprivation therapy. TRE-515's FDA Fast Track designation in this indication provides a pathway for focused clinical development. Its mechanism of targeting nucleotide metabolism may complement existing treatments that target tumor signaling or hormonal pathways. Further evidence on tumor response, progression-free survival, and tolerability will determine whether TRE-515 can offer meaningful benefits beyond existing treatment options.

TRE-515 Recent Developments

In March 2026, the company announced a collaboration with Massachusetts General Hospital to evaluate TRE-515 in up to six patients with advanced ALS through the US Food and Drug Administration’s Expanded Access program.

“TRE-515 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of TRE-515 for potential indication like Solid tumours, Crohn’s disease, Multiple sclerosis, Non-small cell lung cancer, Optic neuritis, and Systemic lupus erythematosus in the 7MM. A detailed picture of TRE-515’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the TRE-515 for potential indications. The TRE-515 market report provides insights about TRE-515’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current TRE-515 performance, future market assessments inclusive of the TRE-515 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of TRE-515 sales forecasts, along with factors driving its market.

TRE-515 Drug Summary

TRE-515 is an investigational, first-in-class, orally administered small-molecule drug developed by Trethera Corporation for the treatment of advanced solid tumors, with additional research exploring its potential in autoimmune and neuroinflammatory diseases. The drug selectively inhibits deoxycytidine kinase (dCK), a key enzyme and rate-limiting step in the nucleoside salvage pathway, which enables cells to recycle nucleosides to produce the nucleotide building blocks required for DNA synthesis. By blocking dCK, TRE-515 aims to disrupt nucleotide availability and DNA replication in cancer cells that depend heavily on this pathway for proliferation and survival. This metabolic approach may also have therapeutic applications in autoimmune diseases, where activated immune cells require increased nucleotide production, and in neuroinflammatory conditions such as amyotrophic lateral sclerosis (ALS). TRE-515 is formulated as an oral capsule intended for once-daily administration, offering a potentially convenient alternative to intravenous anticancer treatments. Its clinical development includes a Phase I dose-escalation study in patients with advanced solid tumors, designed to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity. The report provides TRE-515’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the TRE-515 Market Report

The report provides insights into:

• A comprehensive product overview including the TRE-515 MoA, description, dosage and administration, research and development activities in potential indication like Solid tumours, Crohn’s disease, Multiple sclerosis, Non-small cell lung cancer, Optic neuritis, and Systemic lupus erythematosus.
• Elaborated details on TRE-515 regulatory milestones and other development activities have been provided in TRE-515 market report.
• The report also highlights TRE-515‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The TRE-515 market report also covers the patents information, generic entry and impact on cost cut.
• The TRE-515 market report contains current and forecasted TRE-515 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The TRE-515 market report also features the SWOT analysis with analyst views for TRE-515 in potential indications.

Methodology

The TRE-515 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TRE-515 Analytical Perspective by DelveInsight

• In-depth TRE-515 Market Assessment

This TRE-515 sales market forecast report provides a detailed market assessment of TRE-515 for potential indication like Solid tumours, Crohn’s disease, Multiple sclerosis, Non-small cell lung cancer, Optic neuritis, and Systemic lupus erythematosus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted TRE-515 sales data uptil 2034.

• TRE-515 Clinical Assessment

The TRE-515 market report provides the clinical trials information of TRE-515 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

TRE-515 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

TRE-515 Market Potential & Revenue Forecast

• Projected market size for the TRE-515 and its key indications
• Estimated TRE-515 sales potential (TRE-515 peak sales forecasts)
• TRE-515 Pricing strategies and reimbursement landscape

TRE-515 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• TRE-515 Market positioning compared to existing treatments
• TRE-515 Strengths & weaknesses relative to competitors

TRE-515 Regulatory & Commercial Milestones

• TRE-515 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

TRE-515 Clinical Differentiation

• TRE-515 Efficacy & safety advantages over existing drugs
• TRE-515 Unique selling points

TRE-515 Market Report Highlights

• In the coming years, the TRE-515 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The TRE-515 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TRE-515’s dominance.
• Other emerging products for Solid tumours, Crohn’s disease, Multiple sclerosis, Non-small cell lung cancer, Optic neuritis, and Systemic lupus erythematosus are expected to give tough market competition to TRE-515 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TRE-515 in potential indications.
• Analyse TRE-515 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted TRE-515 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of TRE-515 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of TRE-515? How strong is TRE-515’s clinical and commercial performance?
• What is TRE-515’s clinical trial status in each individual indications such as Solid tumours, Crohn’s disease, Multiple sclerosis, Non-small cell lung cancer, Optic neuritis, and Systemic lupus erythematosus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TRE-515 Manufacturers?
• What are the key designations that have been granted to TRE-515 for potential indications? How are they going to impact TRE-515’s penetration in various geographies?
• What is the current and forecasted TRE-515 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of TRE-515 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to TRE-515 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is TRE-515? What is the duration of therapy and what are the geographical variations in cost per patient?